
    
      Secondary objectives of this clinical trial :

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           inflammation occurring during OSAS, after 3 months of treatment.

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           insulin-resistance associated to OSAS, after 3 months of treatment.

        -  To evaluate the effect of Atorvastatin in comparison with the placebo on the
           hypercholesterolemia associated to OSAS, after 3 months of treatment.

        -  To evaluate at 6 months, the effect of the continuous positive airway pressure (CPAP) +
           Atorvastatin association on the previously cited parameters, in comparison with
           Atorvastatin, CPAP and placebo.

        -  To measure the CPAP efficiency in comparison with sham CPAP in patients receiving the
           placebo, after 3 months of treatment.
    
  